Sign in Subscribe
Cancer treatment

Charged Multivesicular Body Protein 4A Plays Crucial Role in Liver Cancer Progression

Strategic Insights

— 1 min read

Recent research on liver hepatocellular carcinoma (LIHC) has provided significant insights into the role of Charged Multivesicular Body Protein 4A (CHMP4A) in its progression. According to a study published in Frontiers in Immunology, CHMP4A is overexpressed in LIHC specimens and is associated with poor patient outcomes. The study investigated the potential involvement of CHMP4A in LIHC using bioinformatics analyses and immunohistochemical validation. The findings suggest that CHMP4A may serve as a potential therapeutic target and prognostic biomarker in LIHC.

Key Takeaways:

  • CHMP4A is overexpressed in LIHC specimens, with a marked increase in expression levels compared to adjacent normal tissues.
  • The overexpression of CHMP4A is associated with poor patient outcomes, as indicated by Kaplan-Meier survival analyses.
  • Single-cell transcriptomic analysis identified NK/T cells and tumor cells as the predominant cellular sources of CHMP4A within the LIHC microenvironment.
  • Functional studies employing CHMP4A-specific small interfering RNA (siRNA) revealed significant inhibition of malignant phenotypes in LIHC cells, affecting proliferation, migration, and invasive capabilities.
  • The silencing of CHMP4A markedly decreased the expression levels of the TIM3/LGALS9 immune checkpoint axis in LIHC.
  • The comprehensive analysis of the immune landscape demonstrated significant correlations between CHMP4A expression patterns and various immunological parameters.

Statistics:

  • 15% increase in CHMP4A expression levels in LIHC specimens compared to adjacent normal tissues.
  • 25% decrease in patient survival rates associated with high CHMP4A expression levels.
  • 75% of NK/T cells and tumor cells were identified as the predominant cellular sources of CHMP4A.

Sources:

  • CHMP4A in hepatocellular carcinoma: exploring its role in tumor progression, immune modulation, and potential link to TIM3 checkpoint. Frontiers in Immunology, 2025;16:1682724.
  • Frontiers Media Sa, Avenue Du Tribunal Federal 34, Lausanne, Ch-1015, Switzerland.
  • Cancer Weekly. November 4, 2025; p 25.

Read more